Sign up
ESLA

Estrella Immunopharma Inc. (NASDAQ: ESLA)

Healthcare · Biotechnology

$0.33+0.00 (+0.30%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. ESLA rose 0.30% in the Nov 18 session to $0.33. Short interest is 2.43% of float with a 14.72% borrow fee. One active firm covers the stock as of Nov 19, 2026; one active firm with a target averages $8.00 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

MomentumNeutral

RSI (14) 41.0 (overbought above 70, oversold below 30)

Trend—

—

Short interest2.4% of float

FINRA settlement Oct 30, 2026

ESLA price chart

Price $0.33 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$0.34Nov 18, 2026 session
Previous close
$0.33Nov 17, 2026 close
Day range
$0.33 – $0.38Nov 18, 2026 session
52-week range—
Volume
446.60KNov 18, 2026 session
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

ESLA · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 18
Squeeze25Idle—
How the scores work →

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

Insufficient coverage

0Strong Buy
1Buy
0Neutral
0Sell
0Strong Sell

Based on 1 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$8.00
Average$8.00
High$8.00

As of Nov 19, 2026 across 1 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q3 2026−$0.08−$0.17—
Q2 2026−$0.09−$0.05—
Q1 2026—−$0.05—
Annual 2025—−$0.35—
Q3 2025—−$0.13—
Q2 2025—−$0.15—
Q1 2025—−$0.06—
Annual 2024—−$0.27—

Smart-money activity

In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
13FCITADEL ADVISORS LLCClosed position$013F filing
13FRENAISSANCE TECHNOLOGIES LLCReduced position$66.6K13F filing
Insider buyXu JiandongBuy$1.3KForm 4
Insider buyXu JiandongBuy$1.2KForm 4
Insider buyXu JiandongBuy$104Form 4
13FCITADEL ADVISORS LLCIncreased position$100.5K13F filing
13FRENAISSANCE TECHNOLOGIES LLCIncreased position$191.1K13F filing
13FCITADEL ADVISORS LLCReduced position$59.6K13F filing
13FRENAISSANCE TECHNOLOGIES LLCOpened position$12.3K13F filing
13FCITADEL ADVISORS LLCReduced position$43.0K13F filing
All smart-money activity →

News and press releases

All ESLA news →

Company profile

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It

CEO
Ms. Cynthia Pussinen
Headquarters
EmeryVille, CA, United States
Employees
0
IPO date
Sep 14, 2021
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.